studies was confined by their study design being case series, cross-sectional, or case-control with a limited sample size. Although a recent Danish retrospective cohort study showed an increased risk of uveitis associated with psoriasis, the association appeared only in mild psoriasis and psoriatic arthritis but not in severe psoriasis, 17 and there were no other cohort studies to confirm their findings. The relationship between psoriasis and uveitis thus remains unsettled to our knowledge. To evaluate the respective risk estimates of uveitis among people with psoriasis with and without concomitant psoriatic arthritis, we conducted a retrospective nationwide population-based cohort study. We further evaluated the risk of uveitis among those with mild and severe psoriasis, respectively.
Methods

Data Source
The National Health Insurance (NHI) is a compulsory singlepayer health care system that covers more than 99% of the Taiwanese population. The National Health Insurance Research Database (NHIRD) provides anonymized linked data from the NHI for epidemiologic research, encompassing the registration and demographic data of enrollees, health care services data from hospitals and general practices, and medication dispensation data from hospitals, general practices, and community pharmacies. The NHIRD provides diagnosis data coded using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). The accuracy and completeness of the claim data of the NHIRD, including the ICD-9-CM diagnoses and medication records, have been validated. 18, 19 The NHIRD has been extensively used in thousands of published epidemiological studies. 20 We identified psoriatic patients from a specialized data set that contained all people with psoriasis from 2000 to 2011 in the NHIRD. The nonpsoriatic controls were selected from the 2005 Longitudinal Health Insurance Database that provides longitudinally linked anonymized data of 1 000 000 enrollees (nearly 5% of Taiwan's population) randomly sampled from the 2005 Registry for Beneficiaries of the NHIRD. The Longitudinal Health Insurance Database has been validated as a representative sample of the Taiwanese population in terms of age, sex, and average payroll bracket. 21 This study was approved by the institutional review board of the Chang Gung Medical Foundation (104-3810B). As all the data were anonymized, informed consent was exempted.
Study Population
The selection of study participants is shown in Figure 1 . Participants with psoriasis were identified from the NHIRD by using ICD-9-CM codes 696, 696.1, and 696.8. These codes have been adopted in previous epidemiological studies that used the NHIRD. 7, [22] [23] [24] We excluded people for whom psoriasis was diagnosed before 2000 to prevent overestimating the risk of incident uveitis (if the risk of uveitis rises with a longer disease duration of psoriasis, including those who received a diagnosis of psoriasis before 2000 would have overestimated the risk of incident uveitis) and excluded those for whom psoriasis was diagnosed after 2011 to ensure an at least 1-year follow-up duration. The nonpsoriatic control group consisted of people who had never received a diagnosis of psoriasis from the 2005 Longitudinal Health Insurance Database.
We also excluded people with a history of uveitis or the lifetime comorbidities that might have caused uveitis: human immunodeficiency virus infection (ICD-9-CM codes 042-044), ankylosing spondylitis (ICD-9-CM code 720.0), Behçet syndrome (ICD-9-CM codes 136.1, 711.1, 711.2), cytomegalovirus infection (ICD-9-CM code 078.5), herpes zoster ophthalmicus (ICD-9-CM code 053.2), histoplasmosis (ICD-9-CM codes 115.x), Kawasaki disease (ICD-9-CM code 446.1), juvenile rheumatoid arthritis(ICD-9-CM codes 714.x), sarcoidosis (ICD-9-CM codes 135.x, 321.4), syphilis (ICD-9-CM codes 090-097, 647.0), toxoplasmosis (ICD-9-CM codes 130.x), tuberculosis of the eye (ICD-9-CM code 017.3), ulcerative colitis (ICD-9-CM codes 556.x), Crohn disease (ICD-9-CM codes 555.x), and systemic lupus erythematosus (ICD-9-CM code 710.0). 25 We mitigated potential selection bias between the psoriasis and nonpsoriatic groups via 1 to 1 matching by age (±180 days) and sex. Each participant with psoriasis was matched with 1 nonpsoriatic control who had not received a diagnosis of uveitis before the index date. The index date for the group with psoriasis was the date when psoriasis was diagnosed for the first time, whereas the index date for the nonpsoriatic control was the psoriasis-diagnosed date of the matched patient with psoriasis.
We divided the group with psoriasis into 2 groups according to the presence or absence of concomitant psoriatic arthritis: the group with psoriasis with psoriatic arthritis and the group with psoriasis without psoriatic arthritis. The ICD-9-CM code 696.0 was used to identify people who had received diagnoses of psoriatic arthritis. The 2 groups were further divided into 2 subgroups based on treatment patterns: the group with severe psoriasis was composed of people who had received systemic therapy (including acitretin, methotrexate, cyclosporine, etanercept, adalimumab, and ustekinumab) and/or phototherapy, and the group with mild psoriasis consisted of people who had not received systemic therapy or phototherapy. The classification of psoriasis based on treatment patterns has been widely adopted in previous epidemiological studies. 7, [22] [23] [24] [26] [27] [28] [29] [30] 
Key Points
Question Do people with psoriasis have an increased risk of incident uveitis?
Findings In this cohort study including 147 954 participants with psoriasis and 147 954 nonpsoriatic controls from Taiwan, people with concurrent severe psoriasis and psoriatic arthritis had the greatest risk of developing incident uveitis, followed by those with severe psoriasis but without psoriatic arthritis and those with mild psoriasis and psoriatic arthritis. There was not an increased risk for incident uveitis with mild psoriasis but without psoriatic arthritis.
Meaning
The risk of incident uveitis differs with different inflammatory presentations on the spectrum of psoriatic disease.
Outcomes
The outcome of our interest was incident uveitis (ICD-9-CM codes 360. 01 The length of follow-up for people who developed incident uveitis was the period from the index date to the date of first diagnosis of uveitis in inpatient or outpatient records. The censored time of people who did not have uveitis was the period from the index dates to either December 31, 2012, or the date of withdrawal from the NHI. To enhance the accuracy of outcomes, we confirmed the end point by requiring records of the diagnosis on at least 2 outpatient visits or 1 hospital admission.
Statistical Analysis
We examined the baseline characteristics that included age, sex, comorbidity, and medication of psoriasis among the matched cohort. The categorical and continuous data were compared by using the χ 2 test and an analysis of variance test, respectively. We calculated the incidence (per 100 000 person-years) by dividing the number of people with incident uveitis by the person-years of each group. The Poisson distribution was used to obtain the confidence interval and compare the incidence between groups. 31 We used the Kaplan-Meier method for survival analysis and the log-rank test to compare the risk of incident uveitis between various groups with psoriatic disease.
In the primary analysis, we used univariate and multivariate Cox proportional hazard models to estimate the hazard ratios (HR) and 95% confidence intervals for the association between psoriasis status and incident uveitis using the nonpsoriatic control group as the reference. In the multivariate analysis, we adjusted potential confounders including age, sex, type 2 diabetes mellitus, hypertension, and hyperlipidemia.
Some of the ICD-9-CM codes of outcomes may refer to subtypes of uveitis that are not considered associated with psoriasis or psoriatic arthritis. Therefore, we conducted a sensitive analysis by using more selective ICD-9-CM codes (including 360.11, 360.12, 362.18, 363.0x, 363.1x, 363.2x, 364.0. 364.00, 
Results
The characteristics and confounders of the study participants are shown in Table 1 . Of the data collected from January 1, 2000, to December 31, 2012, we included 147 954 people with psoriasis (including 10 107 with concomitant psoriatic arthritis and 137 847 without psoriatic arthritis) and 147 954 matched nonpsoriatic controls. The study population was predominantly Han Chinese. Because of the use of matching among selected study participants, the age and sex distribution was comparable across all groups. The mean (SD) age in the group with psoriasis and the control groups was 44.4 (19.8) years, and women accounted for 41.2% (n = 121 878) of both groups. Compared with the nonpsoriatic controls, a higher proportion of participants with psoriasis had type 2 diabetes mellitus, hypertension, and hyperlipidemia (P < .001).
As demonstrated in Table 2 , the group with psoriasis with psoriatic arthritis and the group with psoriasis without psoriatic arthritis had a higher incidence of uveitis compared with the control group (160.88 and 103.99 vs 87.23 per 10 5 personyears). When further stratified by the severity of psoriasis, the group with severe psoriasis with psoriatic arthritis had the highest incidence of uveitis compared with other groups with psoriasis (185.55 vs 125.11, 126.39, and 99.08 per 10 5 personyears). The Kaplan-Meier curves of cumulative incidence of uveitis are illustrated in Figure 2 . The group with psoriasis with psoriatic arthritis and the group with psoriasis without psoriatic arthritis had a higher risk for incident uveitis than the nonpsoriatic controls (P < .01, Figure 2A ). When further stratified according to the severity of psoriasis, all 4 groups had a higher risk for incident uveitis than the nonpsoriatic controls (P < .05, Figure 2B ). As shown in Table 2 , the primary analysis demonstrated that the group with psoriasis with psoriatic arthritis had an increased risk of incident uveitis (crude HR, 1.84; 95% CI, 1.52-2.24), as well as the group with psoriasis without psoriatic arthritis (crude HR, 1.19; 95% CI, 1.09-1.30) when compared with nonpsoriatic controls. After adjustment for potential confounders, the group with psoriasis with psoriatic arthritis and psoriasis and the group without psoriatic arthritis had a higher risk for incident uveitis (adjusted HR, 1.95; 95% CI, 1.61-2.37; and 1.16; 95% CI, 1.06-1.26, respectively) compared with nonpsoriatic controls. We found a stepwise increase in the risk of incident uveitis from nonpsoriatic controls to psoriasis alone to psoriasis with concomitant psoriatic arthritis (P < .001, χ 2 test for trend).
When further stratified by the severity of psoriasis, the group with severe psoriasis with concomitant psoriasis arthritis had the greatest risk of incident uveitis compared with the nonpsoriatic controls (crude HR, 2.14; 95% CI, 1.70-2.70; adjusted HR, 2.40; 95% CI, 1.90-3.02), and the group with severe psoriasis without psoriatic arthritis and the group with mild psoriasis with concomitant psoriatic arthritis had a higher risk of incident uveitis than the nonpsoriatic controls (adjusted HR, 1.42; 95% CI, 1.23-1.64; and 1.42; 95% CI, 1.03-1.96, respectively). However, an increased risk for incident uveitis with mild psoriasis without psoriatic arthritis was not identified after adjusting for potential confounders (adjusted HR, 1.09; 95% CI, 1.00-1.20). An increasing trend for incident uveitis across these groups was found (P < .001, χ 2 test for trend).
As illustrated in Table 3 , the sensitivity analysis confirmed both psoriatic patients with and without concomitant psoriatic arthritis had an increased risk of incident uveitis (adjusted HR, 1.88; 95% CI, 1.54-2.31; and 1.15; 95% CI, 1.05-1.26, respectively). The sensitivity analysis also identified an increasing trend for uveitis from nonpsoriatic controls to psoriasis alone to psoriasis with concomitant psoriatic arthritis (P < .001, χ 2 test for trend). The sensitivity analysis also found that when compared with nonpsoriatic controls, the group with severe psoriasis with psoriatic arthritis had the highest risk of incident uveitis (adjusted HR, 2.38; 95% CI, 1.87-3.03), followed by the group with severe psoriasis without psoriatic arthritis (adjusted HR, 1.46; 95% CI 1.26-1.70) and the group with mild psoriasis with psoriatic arthritis (adjusted HR, 1.29; 95% CI 0.91-1.84). However, an increased risk for incident uveitis among the group with mild psoriasis without psoriatic arthritis was not found (adjusted HR, 1.08; 95% CI, 0.98-1.19). The sensitivity analysis also found an increasing trend for incident uveitis across these groups (P < .001, χ 2 test for trend).
Discussion
Over the past decade, there has been an increasing awareness of the comorbidities of psoriasis. 7 The term psoriatic disease was introduced to highlight its multiorgan involvement. 32 Although the association between psoriatic arthritis and uveitis is well-known, the relation between uveitis and psoriasis without psoriatic arthritis, to our knowledge, was rarely examined. 11 This study adds evidence for this previously unsettled question. We found that people with concurrent severe psoriasis and psoriatic arthritis (ie, those with the most severe inflammatory presentation of psoriatic disease) have the highest risk for incident uveitis. People with severe psoriasis but without psoriatic arthritis and people with mild psoriasis and psoriatic arthritis (ie, those with a moderately inflammatory presentation on the spectrum of psoriatic disease) also have an increased risk of incident uveitis. By contrast, an increased risk for incident uveitis among people with mild psoriasis but without psoriatic arthritis (ie, those with the mildest inflammatory presentation on the spectrum of psoriatic disease) was not found. The sensitivity analysis adopting more selective diagnostic codes for uveitis confirmed the results of the primary analysis. These findings suggest that the risk of incident uveitis, a condition of intraocular inflammation, increases with the degree of inflammation of psoriatic disease that may present either on the skin or a joint.
Our study results are incongruent with a previous Turkish study that found no association between uveitis and psoriasis. 16 However, our study has the strength of the cohort study design, which provides a higher level of causality evidence than the amine the risk for different severities of psoriasis.
Our study indicates that besides psoriatic arthritis, severe psoriasis is an important marker of inflammation associated with incident uveitis. In this aspect, our study is in congruent with the Singaporean study that found that the severity of psoriasis correlated with the presence of uveitis. 15 A recent Danish study found that the risk of uveitis increased in mild psoriasis without arthritis (adjusted incidence rate ratio, 1.38; 95% CI, 1.11-1.70), but not in severe psoriasis without arthritis (adjusted incidence rate ratio, 1.40; 95% CI, 0.70-2.81), 17 which appears to contradict the wellrecognized greater degree of systemic inflammation in severe psoriasis. 34 While the Danish study only adjusted for 3 comorbidities (herpes zoster, inflammatory bowel disease, and sarcoidosis) in its statistical analysis, 17 our study controlled for a variety of confounding comorbidities by limitation to obtain a less biased estimate of the risk of uveitis (see Study Population in the Methods section).
Limitations
There are a few limitations in this study. First, we used the ICD-9-CM codes to identify cases of psoriasis and psoriatic arthritis; so did other epidemiological studies. 17, [22] [23] [24] 26, 27, 30 One previous study demonstrated that the sensitivity of the ICD-9-CM code for detecting psoriatic arthritis was 73%. 35 Therefore, some patients with psoriasis with psoriatic arthritis might have been misclassified and included in the group with psoriasis without psoriatic arthritis. However, this misclassification only led to an underestimation of the risk of incident uveitis in the group with psoriasis with psoriatic arthritis. Second, similar to other claim databases for epidemiological studies, 26, 27, 30 the data source of this study, the NHIRD, did not provide direct clinical data to determine the severity of psoriasis. As has been widely adopted in previous studies on psoriasis, 7,22-24,26-30 we used treatment patterns to identify mild and severe psoriasis. If we misclassified cases of severe psoriasis as mild psoriasis, the association found between uveitis and severe psoriasis would have been underestimated. Third, when we excluded psoriasis diagnosed before 2000 to avoid overestimating the risk of incident uveitis, it is likely that people with early-onset psoriasis (eg, adults who first presented with psoriasis in childhood) were also excluded. However, we adopted a survival analysis and have considered the duration of psoriasis as a factor in the development of uveitis. Fourth, the exclusion of patients with a history of uveitis from the cohort with psoriasis presumably has led to an underestimation of the overall uveitis burden in the group with psoriasis. Fifth, the definition of severe psoriasis was a history of receiving phototherapy and/or systemic treatments, including cyclosporine and biologics. The 2 latter kinds of drugs are also indicated for treating established uveitis, and thus might well have reduced the risk of uveitis among this group and led to an underestimation of the "true" risk of uveitis among the group with severe psoriasis. Sixth, the study participants were censored after their first attack of uveitis. These participants may have had further attacks and a higher disease burden than detected in this study. Seventh, human leukocyte antigen B27 has been associated with uveitis, 13 but we were unable to adjust for it because the NHIRD does not SP with PA (LR, P <.01) MP with PA (LR, P =.02) SP without PA (LR, P <.01) MP without PA (LR, P <.01) NC P with PA (LR, P <.01) P without PA (LR, P <.01) NC 
